Compare Edwards Lifesciences Corporation Common Stock (EW) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.06 (market cap $49.15B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 5.5× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 3,642,969). Which is the better fit depends on your goals.
| EW | KYMR | |
|---|---|---|
Market Cap | $49.15B | $8.87B |
Volume | 3,642,969 | 779,107 |
Sector | Health | Health |
52-Week High | $95.18 | $127.31 |
52-Week Low | $72.65 | $55.80 |
Enterprise Value | $45.60B | $8.26B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
